Novartis will present data from five key abstracts on Rhapsido (remibrutinib), a highly selective oral BTKi, at the AAAAI Annual Meeting in Philadelphia from February 27 to March 2, 202615.
New Phase III REMIX-1 and REMIX-2 analyses show remibrutinib improves disease control and provides rapid symptom relief in chronic spontaneous urticaria (CSU)235.
Phase II data on remibrutinib for IgE-mediated peanut allergy will be featured in an oral session, with Phase III program planned for 2026135.
Remibrutinib is in development for chronic inducible urticaria (CIndU), with FDA submission completed for symptomatic dermographism in Q4 2025 and positive topline results from the Phase III RemIND trial156.
Recent FDA approval for CSU; regulatory reviews underway in EU and Japan5.
Additional development in hidradenitis suppurativa (HS)245.
Sources:
1. https://www.marketscreener.com/news/novartis-presents-rhapsido-remibrutinib-data-at-aaaai-showing-potential-beyond-chronic-spontane-ce7e5dd2d181f72c
2. https://practicaldermatology.com/news/remibrutinib-data-at-aaaai-highlight-expanded-potential-beyond-csu/2485784/
3. https://www.gurufocus.com/news/8641137/novartis-nvs-showcases-new-rhapsido-data-at-aaaai-meeting
4. https://www.snsinsider.com/blogs/novartis-showcases-rhapsido-data-at-aaaai
5. https://www.novartis.com/news/media-releases/novartis-presents-rhapsido-remibrutinib-data-aaaai-showing-potential-beyond-chronic-spontaneous-urticaria-csu
6. https://www.nasdaq.com/articles/novartis-presents-5-key-abstracts-evaluating-rhapsido-csu-peanut-allergy-aaaai-annual-meet